A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
Novartis
Bristol-Myers Squibb
Novartis
Revolution Medicines, Inc.
University of Chicago
Revolution Medicines, Inc.
Erasca, Inc.
Allist Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Genfleet Therapeutics (Shanghai) Inc.
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Eli Lilly and Company
Sun Yat-sen University
Bristol-Myers Squibb
Sun Yat-sen University
Nektar Therapeutics
Menarini Group
NuCana plc
HiberCell, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Zhejiang Cancer Hospital
Sun Yat-sen University
Roswell Park Cancer Institute
Eli Lilly and Company
NSABP Foundation Inc
Taiwan Leader Biotech Corp.
NKGen Biotech, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Amsterdam UMC, location VUmc
Daiichi Sankyo
Gilead Sciences
Western Regional Medical Center
Institut du Cancer de Montpellier - Val d'Aurelle
Seagen Inc.
Stanford University
University College, London
Array BioPharma
Massachusetts General Hospital
Bristol-Myers Squibb
Federation Francophone de Cancerologie Digestive
Merck KGaA, Darmstadt, Germany
Bristol-Myers Squibb
Odense University Hospital
Hoosier Cancer Research Network